In recent years, advancements in single-cell and spatial transcriptomics, which are highly
regarded developments in the current era, particularly the emerging integration of single-cell …

Transcription factors (TFs) represent the most commonly deregulated DNA-binding class of
proteins associated with multiple human cancers. They can act as transcriptional activators …

The transcription factor MYC is overexpressed in most cancers, where it drives multiple
hallmarks of cancer progression. MYC is known to promote oncogenic transcription by …

Simple Summary Prostate cancer remains a leading cause of death in men worldwide.
Polyploid giant cancer cells (PGCCs) and chromosomal instability have been proposed to …

Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate
cancer. Sialyltransferases have been shown across several solid tumours, including breast …

Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR)
signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop …

Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen
signaling. Androgen deprivation therapy and second-generation androgen receptor (AR) …

Dysregulation of alternative splicing in prostate cancer is linked to transcriptional programs
activated by AR, ERG, FOXA1, and MYC. Here, we show that FOXA1 functions as the …

Heterogeneous response to Enzalutamide, a second-generation androgen receptor
signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) …

Simple Summary Bone metastases and health are crucial issues in prostate cancer patient
management. The aim of our review was to describe the biology of bone metastases and …